OncLive TV

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the use of agents in ovarian cancer that are not approved by the FDA.

Laurie Gaspar, MD, professor and chair of the Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the treatment of brain metastases in patients with lung cancer.

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the decision regarding the timing of treatment with aflibercept for patients with colorectal cancer.

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses the treatment of melanoma.

Michael Gnant, MD, professor of the Department of Surgery at the Medical University of Vienna in Vienna, Austria, discusses the four intrinsic subtypes of the PAM50 recurrence score test and a clinical trial comparing this test with OncotypeDX.

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses the role of PARP inhibitors in ovarian cancer.

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center in Tampa, Florida, talks about personalized medicine when treating patients with melanoma.

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, explains excitement over the potential role for next-generation sequencing in cancer care.

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the utility of aflibercept in patients with advanced colorectal cancer.

Russell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses PARP inhibitors and their potential role in gynecologic cancers.

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted therapies in renal cell carcinoma (RCC).

Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses new and emerging treatments for metastatic melanoma

Josep Tabernero, MD, PhD, of Vall d'Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, says that it is an exciting time for the treatment of patients with metastatic breast cancer.

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, discusses the challenges and recent advancements of treating patients with triple-negative breast cancer.

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing for melanoma.

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, explains how the endpoints of progression-free survival (PFS) and overall survival (OS) are holding back the approval of drugs for patients with ovarian cancer.

Viktor Grünwald, MD, PhD, an attending physician at the Hannover Medical School, discusses tumor remission in patients with renal cell carcinoma (RCC).

Debu Tripathy, MD, co-leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses integrative oncology

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses the need for collaboration in cancer research.

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, discusses testing for genetic mutations in patients with melanoma.

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer.

Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses the role of robotic surgery in gynecologic cancer.

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the role of the pathologist in the treatment of a patient with melanoma.

Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).

Robert A. Burger, MD, FACOG, FACS, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses treating elderly patients with colorectal cancer with aflibercept.

Corey J. Langer, MD, professor of medicine, hematology/oncology division, University of Pennsylvania, Abramson Cancer Center, discusses the treatment of patients with early stage lung cancer.

Omid Hamid, MD, discusses using immune therapy to treat patients with melanoma.

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.